

Influenza vaccine procurement systems for seasonal campaigns in Europe



DRIVE
Development of Robust and Innovative Vaccine Effectiveness

Anke L Stuurman ^a, Caterina Rizzo ^b, Mendel DM Haag ^c

^a P95 Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium; ^b Bambino Gesù Children's Hospital, Rome Italy (ECDC National Focal Point For Influenza and Other Respiratory viruses Program); ^c Seqirus, Amsterdam, The Netherlands.


Objective: to describe seasonal influenza vaccine procurement systems for the national campaigns and how it informs on brand availability to support brand-specific vaccine effectiveness studies

Structured telephone surveys


- Oct 2017-Apr 2018
- 6 public and 5 private stakeholder experts

Four main procurement systems in 14 European countries were identified

- National tenders
- Regional tenders
- Purchase by GPs
- Purchase by pharmacies




Brand availability at national, regional and clinic level by procurement system - number of brands and proportion of each



--- Proportions for illustration only: actual proportions not publicly available and may vary.

Separate ●: separate pediatric vaccine procurement. [±]Ca. 7-8 brands; [£]Nr of Regions: Italy=21, Spain=17, Sweden=10; *Proportions vary; ⁺Nr of brands varies; [¥]Greece: Nr of brands not publicly available

Timeliness and public availability of procurement information




✂ Start of vaccination campaigns

* Oct-Dec in year prior to vaccination campaign of interest

+ Difficult to find and often published late

In conclusion: can public procurement information help determine ahead of campaigns which brand will be used where at clinic level?

- Yes
- Yes but % varies across clinics (NLD, DNK), or unclear where data is accessible (SWE)
- No



Support: EU/EFPIA Innovative Medicines Initiative-2 Joint Undertaking; DRIVE, grant n°77736.

Contact: www.drive-eu.org anke.stuurman@p-95.com